We use technology to improve diagnostic and treatment accuracy for patients. We develop state of the art solutions to improve clinical outcome, and hence improve quality of life.
Biobot Surgical Pte Ltd aims to be a global technology leader in minimally-invasive robotic healthcare solutions.
Biobot Surgical Pte Ltd was incorporated in 2007 in Singapore, and became a member of Zicom Group since 2011.
To ensure success, a team of talents has been put together in the areas of robotic design and technology, medical image processing, software development and clinical application. In addition, Zicom leveraged its in-house intellectual property (IP) translation services and manufacturing infrastructure from iPtec to support the project.
To date, the iSR’obot Mona Lisa has obtained key regulatory approvals, including Europe (CE mark), U.S.A (US FDA), Australia (TGA) and Singapore (HSA) and is being used in some of the most prestigious hospitals around the world.
Striving to become the gold standard in diagnosis and prognosis of prostate cancer, the Mona Lisa’s development has been a process of evolution and is the latest in our state of the art new generation designs.
The Royal Adelaide Hospital is trialing the Mona Lisa.
The Mona Lisa undergoes a pilot pre-clinical project on focal therapy for prostate cancer treatment with The University of Alabama at Birmingham. It is one of two beta sites in the United States.
Mona Lisa is one of the success stories in Singapore’s medtech scene
Mona Lisa helps Singapore General Hospital achieve an increase from 70% to 90% accuracy in biopsy tests for cancer.